RAFAT HOROUB, ALİREZA SHAMSAEEFAR, MASOOD DEHGHANİ, HAMED NİKOOPOUR, MAJİD ENTEZARİ, ALİ MORADİ, KOUROSH KAZEMİ, AHAD ESHRAGHİAN, SAMAN NİKEGHBALİAN, SEYED ALİ MALEK-HOSSEİNİ
Experimental and Clinical Transplantation - 2021;19(5):445-449
Objectives: Primary hyperoxaluria type 1 is an autosomal recessive disorder that causes over - production and urinary excretion of oxalate. Liver transplant has been suggested as a treatment for primary hyperoxaluria type 1 since the defective enzyme is expressed in the liver. This study aimed to investigate results of combined liver and kidney, sequential, and preemptive liver transplant in patients with primary hyperoxaluria type 1. Materials and Methods: In this cohort study, we followed patients with primary hyperoxaluria type 1 who underwent liver transplant at our center in Shiraz, Iran. Clinical and laboratory data of patients were gathered, and major outcomes, including renal failure after liver transplant, rejection, and mortality were recorded. Survival of patients was analyzed by the Kaplan-Meier method. Results: Our study included 24 patients. There were 16 male (66.6%) and 8 female (33.33%) patients. Thirteen patients were in the pediatric age group (age < 18 y), and 11 patients were adults (age ≥ 18 y). Thirteen patients underwent sequential transplant, 8 patients underwent combined liver and kidney transplant, and 3 patients underwent preemptive transplant. All patients received organs from deceased donors. There were no statistically significant differences in mortality, rejection, and hemodialysis after transplant between those with sequential transplant and those with combined liver and kidney transplant (P > .05). Conclusions: Liver transplant can be considered a treatment for patients with primary hyperoxaluria type 1. Combined liver and kidney transplant and preemptive liver transplant could be proper options for these patients.
